CVRx Unveils New Data on Barostim Therapy at THT 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy CVRX?
Source: Newsfilter
- Clinical Data Presentation: CVRx will showcase new clinical data on Barostim therapy at the 2026 Technology and Heart Failure Therapeutics meeting, featuring six-month outcomes from over 400 patients, demonstrating the therapy's safety and efficacy in heart failure patients.
- Scientific Presentations: The conference will include multiple presentations on Barostim therapy, analyzing cardiac energetics and hospitalization impacts, highlighting the therapy's potential in improving left ventricular ejection fraction (LVEF), which could set new standards in heart failure treatment.
- Satellite Program Highlights: CVRx will host a satellite program during the conference to present updates on the REBALANCE Registry data and the BREATHE-HF and BENEFIT-HF trials, the latter aiming to evaluate Barostim's impact in a significantly larger heart failure population, which holds substantial clinical significance.
- Increasing Market Acceptance: CVRx CEO Kevin Hykes noted the accelerating acceptance of Barostim within the heart failure community, with a growing number of publications validating the therapy's positive patient impact, indicating a promising expansion of market potential.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CVRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CVRX
Wall Street analysts forecast CVRX stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 8.220
Low
11.00
Averages
12.50
High
14.00
Current: 8.220
Low
11.00
Averages
12.50
High
14.00
About CVRX
CVRx, Inc. is a commercial-stage medical device company. The Company is focused on developing, manufacturing and commercializing advanced neuromodulation solutions for patients with cardiovascular diseases. The Company's integrated platform technology, Barostim, is designed to leverage the power of the brain and nervous system to address the imbalance of the autonomic nervous system (ANS), which causes heart failure with reduced ejection fraction (HFrEF) and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy (BAT) by sending imperceptible and persistent electrical pulses to baroreceptors located in the wall of the carotid artery to signal the brain to modulate cardiovascular function. Barostim is a minimally invasive neuromodulation device that consists of two implantable components, an implantable pulse generator (IPG) and a stimulation lead, and is programmed by a wireless clinician-controlled programmer that communicates with the IPG.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
CVRx Unveils New Data on Barostim Therapy at THT 2026
- Clinical Data Presentation: CVRx will showcase new clinical data on Barostim therapy at the 2026 Technology and Heart Failure Therapeutics meeting, featuring six-month outcomes from over 400 patients, demonstrating the therapy's safety and efficacy in heart failure patients.
- Scientific Presentations: The conference will include multiple presentations on Barostim therapy, analyzing cardiac energetics and hospitalization impacts, highlighting the therapy's potential in improving left ventricular ejection fraction (LVEF), which could set new standards in heart failure treatment.
- Satellite Program Highlights: CVRx will host a satellite program during the conference to present updates on the REBALANCE Registry data and the BREATHE-HF and BENEFIT-HF trials, the latter aiming to evaluate Barostim's impact in a significantly larger heart failure population, which holds substantial clinical significance.
- Increasing Market Acceptance: CVRx CEO Kevin Hykes noted the accelerating acceptance of Barostim within the heart failure community, with a growing number of publications validating the therapy's positive patient impact, indicating a promising expansion of market potential.
See More
Pomerantz LLP Investigates CVRx for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating CVRx and its executives for potential securities fraud or unlawful business practices, which could lead to significant losses for investors.
- Poor Performance Impact: CVRx's preliminary first-quarter results announced on April 7, 2025, fell short of expectations, causing the stock price to plummet by 46.3% to $6.20 per share on April 8, reflecting market concerns over the development of the company's sales representatives.
- Sales Team Changes: In the earnings report on May 8, 2025, CVRx lowered its full-year revenue guidance, with CEO Hykes noting that 25% of territory managers were newly hired between December and March, indicating that the impact of sales team changes was more significant than initially anticipated.
- Continued Stock Decline: Following the disappointing performance, CVRx's stock price fell again by 38.7% to $4.77 per share on May 9, 2025, highlighting a lack of investor confidence in the company's future prospects.
See More
Pomerantz LLP Investigates CVRx for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating claims against CVRx and its executives for potential securities fraud or unlawful business practices, which could lead to significant losses for investors.
- Poor Performance Impact: CVRx's preliminary first-quarter results released on April 7, 2025, fell short of expectations, causing the stock price to plummet 46.3% to $6.20 per share the following day, indicating market disappointment with the company's performance.
- Sales Team Changes: On May 8, 2025, CVRx announced weak first-quarter results and lowered its full-year revenue guidance, with the CEO noting that 25% of territory managers were replaced in a short period, highlighting challenges in internal restructuring.
- Continued Stock Decline: Following the poor performance and sales team changes, CVRx's stock price fell another 38.7% to $4.77 per share on May 9, 2025, reflecting investor concerns about the company's future outlook.
See More
Maplight and CVRx Executives Increase Stock Holdings
- Maplight Purchase: George Pavlov of Maplight Therapeutics made a $441,168 purchase of 25,000 shares of MPLT at $17.65 each on Friday, marking his first buy in the past twelve months, indicating confidence in the company's future prospects.
- Market Performance: On Monday, Maplight Therapeutics' stock traded down approximately 1.4%, and while Pavlov's purchase may not have immediately boosted the stock price, his long-term investment intentions could influence market sentiment.
- CVRx Purchase: Mudit K. Jain also bought $297,592 worth of CVRx, acquiring 46,800 shares at $6.36 each on Friday, which is his third purchase in the past twelve months, reflecting his ongoing optimism about CVRx.
- Stock Fluctuation: CVRx's stock rose about 12.1% on Monday, reaching a high of $7.22, with Jain's investment up approximately 13.5% at the peak, showcasing a positive market reaction to CVRx.
See More
Pomerantz LLP Investigates CVRx for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating whether CVRx and its executives engaged in securities fraud or other unlawful business practices, which could undermine investor confidence and lead to stock price volatility.
- Disappointing Performance Impact: CVRx announced weaker-than-expected preliminary first-quarter results on April 7, 2025, causing its stock to plummet 46.3% to $6.20 per share the following day, indicating market disappointment with the company's performance.
- Sales Team Changes: During the earnings call on May 8, 2025, CEO Hykes noted significant changes in the sales team, with 25% of territory managers replaced in a short period, raising further concerns about the company's future performance.
- Continued Stock Decline: Following the poor performance and lowered full-year revenue guidance, CVRx's stock fell another 38.7% to $4.77 per share on May 9, 2025, reflecting a pessimistic sentiment among investors regarding the company's outlook.
See More
CVRx Under Investigation for Possible Securities Law Violations
- Performance Decline: CVRx reported only $12.3 million in revenue for Q1 2025, indicating that despite bringing in several high-quality sales representatives, many are still in the early stages of territory development, which has undermined investor confidence.
- Revenue Guidance Cut: On May 8, 2025, CVRx slashed its full-year revenue guidance to between $55 million and $58 million, with management stating that changes in the salesforce were more significant than initially anticipated, raising further concerns about the company's future.
- Stock Price Plunge: Following the poor performance announcement on April 8, CVRx's stock fell by $5.34, a 46.3% drop, and on May 9, the stock fell another $3.01, or 38.8%, severely impacting investor interests.
- Integration Challenges: During the February 12, 2026 earnings call, CVRx noted that integrating new sales representatives has created near-term growth impacts, leading to a stock price decline of $0.74, or 13.0%, highlighting the challenges the company faces in its sales organization.
See More
CVRx Unveils New Data on Barostim Therapy at THT 2026
- Clinical Data Presentation: CVRx will showcase new clinical data on Barostim therapy at the 2026 Technology and Heart Failure Therapeutics meeting, featuring six-month outcomes from over 400 patients, demonstrating the therapy's safety and efficacy in heart failure patients.
- Scientific Presentations: The conference will include multiple presentations on Barostim therapy, analyzing cardiac energetics and hospitalization impacts, highlighting the therapy's potential in improving left ventricular ejection fraction (LVEF), which could set new standards in heart failure treatment.
- Satellite Program Highlights: CVRx will host a satellite program during the conference to present updates on the REBALANCE Registry data and the BREATHE-HF and BENEFIT-HF trials, the latter aiming to evaluate Barostim's impact in a significantly larger heart failure population, which holds substantial clinical significance.
- Increasing Market Acceptance: CVRx CEO Kevin Hykes noted the accelerating acceptance of Barostim within the heart failure community, with a growing number of publications validating the therapy's positive patient impact, indicating a promising expansion of market potential.
See More
Pomerantz LLP Investigates CVRx for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating CVRx and its executives for potential securities fraud or unlawful business practices, which could lead to significant losses for investors.
- Poor Performance Impact: CVRx's preliminary first-quarter results announced on April 7, 2025, fell short of expectations, causing the stock price to plummet by 46.3% to $6.20 per share on April 8, reflecting market concerns over the development of the company's sales representatives.
- Sales Team Changes: In the earnings report on May 8, 2025, CVRx lowered its full-year revenue guidance, with CEO Hykes noting that 25% of territory managers were newly hired between December and March, indicating that the impact of sales team changes was more significant than initially anticipated.
- Continued Stock Decline: Following the disappointing performance, CVRx's stock price fell again by 38.7% to $4.77 per share on May 9, 2025, highlighting a lack of investor confidence in the company's future prospects.
See More
Pomerantz LLP Investigates CVRx for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating claims against CVRx and its executives for potential securities fraud or unlawful business practices, which could lead to significant losses for investors.
- Poor Performance Impact: CVRx's preliminary first-quarter results released on April 7, 2025, fell short of expectations, causing the stock price to plummet 46.3% to $6.20 per share the following day, indicating market disappointment with the company's performance.
- Sales Team Changes: On May 8, 2025, CVRx announced weak first-quarter results and lowered its full-year revenue guidance, with the CEO noting that 25% of territory managers were replaced in a short period, highlighting challenges in internal restructuring.
- Continued Stock Decline: Following the poor performance and sales team changes, CVRx's stock price fell another 38.7% to $4.77 per share on May 9, 2025, reflecting investor concerns about the company's future outlook.
See More
Maplight and CVRx Executives Increase Stock Holdings
- Maplight Purchase: George Pavlov of Maplight Therapeutics made a $441,168 purchase of 25,000 shares of MPLT at $17.65 each on Friday, marking his first buy in the past twelve months, indicating confidence in the company's future prospects.
- Market Performance: On Monday, Maplight Therapeutics' stock traded down approximately 1.4%, and while Pavlov's purchase may not have immediately boosted the stock price, his long-term investment intentions could influence market sentiment.
- CVRx Purchase: Mudit K. Jain also bought $297,592 worth of CVRx, acquiring 46,800 shares at $6.36 each on Friday, which is his third purchase in the past twelve months, reflecting his ongoing optimism about CVRx.
- Stock Fluctuation: CVRx's stock rose about 12.1% on Monday, reaching a high of $7.22, with Jain's investment up approximately 13.5% at the peak, showcasing a positive market reaction to CVRx.
See More
Pomerantz LLP Investigates CVRx for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating whether CVRx and its executives engaged in securities fraud or other unlawful business practices, which could undermine investor confidence and lead to stock price volatility.
- Disappointing Performance Impact: CVRx announced weaker-than-expected preliminary first-quarter results on April 7, 2025, causing its stock to plummet 46.3% to $6.20 per share the following day, indicating market disappointment with the company's performance.
- Sales Team Changes: During the earnings call on May 8, 2025, CEO Hykes noted significant changes in the sales team, with 25% of territory managers replaced in a short period, raising further concerns about the company's future performance.
- Continued Stock Decline: Following the poor performance and lowered full-year revenue guidance, CVRx's stock fell another 38.7% to $4.77 per share on May 9, 2025, reflecting a pessimistic sentiment among investors regarding the company's outlook.
See More
CVRx Under Investigation for Possible Securities Law Violations
- Performance Decline: CVRx reported only $12.3 million in revenue for Q1 2025, indicating that despite bringing in several high-quality sales representatives, many are still in the early stages of territory development, which has undermined investor confidence.
- Revenue Guidance Cut: On May 8, 2025, CVRx slashed its full-year revenue guidance to between $55 million and $58 million, with management stating that changes in the salesforce were more significant than initially anticipated, raising further concerns about the company's future.
- Stock Price Plunge: Following the poor performance announcement on April 8, CVRx's stock fell by $5.34, a 46.3% drop, and on May 9, the stock fell another $3.01, or 38.8%, severely impacting investor interests.
- Integration Challenges: During the February 12, 2026 earnings call, CVRx noted that integrating new sales representatives has created near-term growth impacts, leading to a stock price decline of $0.74, or 13.0%, highlighting the challenges the company faces in its sales organization.
See More
